TScan Therapeutics, Inc. (TCRX) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for TScan Therapeutics, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Valuation | ||||||
| P/E Ratio | -1.00x | -2.67x | -4.29x | -0.56x | -2.21x | -10.02x |
| P/B Ratio | 1.05x | 1.41x | 2.53x | 0.37x | 0.67x | -6.17x |
| P/S Ratio | 12.58x | 120.90x | 18.17x | 2.75x | 10.61x | 241.34x |
| Profitability | ||||||
| Gross Margin | 72.2% | 100.0% | 100.0% | 100.0% | 100.0% | -1796.5% |
| Operating Margin | -1315.4% | -4787.7% | -444.0% | -492.3% | -479.6% | -2417.8% |
| Net Margin | -1256.8% | -4527.7% | -423.9% | -489.3% | -479.5% | -2408.0% |
| EBITDA Margin | -1287.6% | -4252.1% | -380.5% | -442.6% | -446.7% | -2304.4% |
| Liquidity | ||||||
| Current Ratio | 8.15x | 8.14x | 6.51x | 7.17x | 7.76x | 2.09x |
| Quick Ratio | 8.15x | 8.14x | 6.51x | 7.17x | 7.76x | 2.09x |
| Leverage | ||||||
| Debt/Equity | 0.76x | 0.40x | 0.61x | 0.86x | 0.04x | -0.18x |
YoY = year-over-year change. Source: FMP..